We thank Freund et al. for their thoughtful comments and providing us the opportunity to make important clarifications. In our article, we acknowledged that myoclonic status epilepticus (MSE) and Lance-Adams syndrome are distinct clinical entities. The sentence “one of the distinguishing features of Lance-Adams syndrome is the early onset of MSE”1 lacked clarity and was misinterpreted. We meant to say that the early onset of myoclonus in MSE is a key feature distinguishing it from Lance-Adams syndrome, which is a later phenomenon.